The Skin Anti-Aging Effects of Vitamin K2 (MK-7): a Clinical Split-Face/Neck Trial

February 4, 2026 updated by: Nanjing Ascend Biotech Technology Co., Ltd.

Cosmetic Efficacy Testing

The goal of this clinical trial is to evaluate the efficacy of a facial and neck cream containing Vitamin K2 in improving skin hydration, elasticity, firmness, and reducing wrinkles in 36 female participants aged 35-60 years with concerns of facial dryness, dullness, laxity, and neck lines. The main questions it aims to answer are:

Does the test cream significantly improve skin hydration (Corneometer), reduce transepidermal water loss (Vapometer), and enhance skin elasticity and firmness (Cutometer) compared to a control cream?

Does the test cream significantly reduce wrinkle severity (assessed by Rz and Ra parameters via AEVA-HE rapid optical imaging) in areas including the neck, cheeks, marionette lines, and crow's feet compared to a control cream?

Researchers will compare the test cream (applied to one randomized half-face and neck) to the control cream (applied to the contralateral half-face and neck) to see if the test cream demonstrates superior efficacy in improving the measured skin parameters.

Participants will:

Apply the test cream to one assigned side of the face and neck, and the control cream to the other side, twice daily for 8 weeks.

Attend evaluation visits at baseline, 2, 4, and 8 weeks for instrumental measurements (skin hydration, TEWL, elasticity, rapid optical imaging, facial imaging) and to complete subjective questionnaires.

Study Overview

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beijing, China, 100123
        • Beijing Sino-German Union Cosmetic Institute Co., Ltd.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Is a Chinese female aged between 35 and 60 years (inclusive).
  • Presents with facial skin concerns including dryness, dullness, and laxity.
  • Has crow's feet (outer canthus wrinkles) with a visual assessment grade of 2 to 4 (on a 0-6 scale).
  • Self-reports concerns about neck wrinkles.
  • Is in good general health at the time of screening.
  • Is willing and able to provide written informed consent.
  • Is willing and able to comply with all study procedures and product usage requirements for the duration of the study.

Exclusion Criteria:

  • Is planning pregnancy, is pregnant, lactating, or within 6 months postpartum.
  • Has a history of severe systemic diseases, immunodeficiency, or autoimmune diseases.
  • Has a history of allergic diseases or has experienced cosmetic allergies within the past 1-2 years.
  • Has had dermatological diseases on the test areas (face and neck) or is undergoing related medical treatment within the past 3 months.
  • Has an active cold, influenza, or other acute illness at the study start that may affect participation.
  • Is currently participating, or has participated within the past month, in another clinical study involving the test areas.
  • Is deemed unsuitable for participation by a dermatologist's assessment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo Face-and-Neck Cream
Participants apply the Placebo Face-and-Neck Cream (base formulation without Vitamin K2) to the contralateral half of the face and neck. Used twice daily (morning and evening) for 8 weeks.
This is the control topical cosmetic cream (face and neck cream). It is the base formulation identical to the test cream but without the addition of Vitamin K2. The product is a white to light yellow cream, supplied in plastic bottles. Each participant applies this cream to the contralateral half of the face and neck (opposite to the test product side). The application regimen is twice daily (morning and evening), using approximately 0.5g per application, for a duration of 8 weeks.
Active Comparator: Face-and-Neck Cream
Participants apply the Face-and-Neck Cream (containing 0.05% Vitamin K2) to one randomly assigned half of the face and neck. Used twice daily (morning and evening) for 8 weeks.
This is a topical cosmetic cream (face and neck cream) containing 0.05% BioYoung™ MK-7 (Vitamin K2) as the key active ingredient. The product is a white to light yellow cream, supplied in plastic bottles. Each participant applies this cream to one randomly assigned half of the face and neck. The application regimen is twice daily (morning and evening), using approximately 0.5g per application, for a duration of 8 weeks.
Other Names:
  • Face-and-Neck Cream (with 0.05% BioYoung™ MK-7)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Facial Skin Elasticity (R0, R1 and F4)
Time Frame: At Baseline, Week 2, Week 4, and Week 8

Assessed using a Cutometer MPA580.Measurements are taken on the cheek area. R0 (Uf) represents the maximum skin deformation under suction. A lower R0 value indicates greater resistance to tensile deformation, reflecting superior skin firmness.

R1 (Uf - Ua) quantifies the immediate elastic recovery after suction release. A lower R1 value signifies faster restoration to baseline morphology, demonstrating enhanced skin elasticity.

F4, the viscoelastic fatigue parameter, quantifies energy dissipation during cyclic skin deformation. A lower F4 value indicates enhanced viscoelastic integrity of the skin.

At Baseline, Week 2, Week 4, and Week 8
Change in Roughness Parameters (Ra and Rz ) of Face and Neck Wrinkles
Time Frame: At Baseline, Week 2, Week 4, and Week 8

Assessed by AEVA-HE rapid optical imaging system. Ra represents the arithmetic average of absolute deviations of skin surface profile points from the mean line across the entire assessment length. It quantifies the overall smoothness of the skin surface. Lower Ra values indicate smoother skin with less pronounced wrinkle formation.

Rz is calculated by dividing the skin surface profile into five equal sampling lengths. The parameter represents the arithmetic mean of the distances between the highest peaks and deepest valleys within each segment, quantifying the extreme variations in skin surface topography. As a key indicator of macro-textural irregularities, lower Rz values correspond to reduced skin unevenness.

At Baseline, Week 2, Week 4, and Week 8
Change in Facial Sagging (Mandibular Plane Angle)
Time Frame: At Baseline, Week 2, Week 4, Week 8
Quantified by analyzing standard white-light photographs taken with a VISIA imaging system. The mandibular plane angle is measured in degrees (°) using image analysis software (Image-Pro Plus). An increase in the angle indicates a sharper, more defined, and firmer jawline contour.
At Baseline, Week 2, Week 4, Week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Skin Hydration
Time Frame: At Baseline, Week 2, Week 4, Week 8
Measured by a Corneometer CM825 on the cheek. Values are expressed in arbitrary units (a.u.). A higher value indicates better skin hydration.
At Baseline, Week 2, Week 4, Week 8
Change in Facial Transepidermal Water Loss (TEWL)
Time Frame: At Baseline, Week 2, Week 4, Week 8
Measured in grams per square meter per hour (g/m²h) using a standardized vapometer (Vapometer, SWL5201) under controlled environmental conditions (21 ± 1°C, 50 ± 10% RH). Measurements were taken on the cheek area (zygomatic region). A lower value indicates reduced water loss and improved skin barrier function.
At Baseline, Week 2, Week 4, Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 26, 2024

Primary Completion (Actual)

February 20, 2025

Study Completion (Actual)

May 19, 2025

Study Registration Dates

First Submitted

January 29, 2026

First Submitted That Met QC Criteria

February 4, 2026

First Posted (Actual)

February 11, 2026

Study Record Updates

Last Update Posted (Actual)

February 11, 2026

Last Update Submitted That Met QC Criteria

February 4, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Skin Aging of Face and Neck

Clinical Trials on Placebo Face-and-Neck Cream

Subscribe